In Rare Move, CMS Cites FDA Warning Letter In National Coverage Request
This article was originally published in The Gray Sheet
Executive Summary
CMS' internally-generated national coverage request for infrared therapy devices uncharacteristically refers to a recent FDA warning letter to manufacturer Anodyne Therapy
You may also be interested in...
Sen. Grassley Wants FDA To Give More Info To CMS, Cites Menaflex Case
Controversy over FDA's 2008 clearance of ReGen Biologics' Menaflex knee repair device has now expanded into questions from Congress over how effectively FDA shares information with its sister agency CMS
Sen. Grassley Wants FDA To Give More Info To CMS, Cites Menaflex Case
Controversy over FDA's 2008 clearance of ReGen Biologics' Menaflex knee repair device has now expanded into questions from Congress over how effectively FDA shares information with its sister agency CMS
CMS Contemplates Role Of Responding To Device Safety Concerns
CMS is pondering its responsibility to repeal coverage for medical services or devices when safety concerns surface, leading some to question whether such action could infringe on FDA turf